Purpose: The virus inactivation capacities of the optimised solvent/detergent (S/D) and terminal dry-heat (PermaHeat) treatments, as part of the Wilate® manufacturing process, were determined in this study. Wilate® is a novel, human plasma-derived, VWF/FVIII concentrate, which through the clinical trials has been proven safe and effective in the treatment of von Willebrand disease and haemophilia A patients.

Methods: S/D virus inactivation studies were performed in down-scaled settings using 1% Octoxynol/0.3% TNBP for 4 hours at +23–28°C. PermaHeat was performed at +100°C for 120 min at 0.6% residual moisture in the lyophilisate (0.7–1.6% during regular manufacturing). Robustness conditions were studied for both steps.

Summary of results: S/D treatment revealed the following inactivation ratios [log10]: HIV-1: ≥7.5, SBV: ≥8.6 and PRV: ≥8.5. All enveloped viruses (EV) were inactivated below the detection limits of the infectivity assays already after 2 minutes. Variation of process parameters did not reduce the efficacy of the S/D treatment. For PermaHeat the following inactivation ratios were found at extreme conditions, i.e. low residual moisture [log10]: EV: HIV-1: ≥5.8, SBV: ≥5.5 and PRV: 4.9 - NEV (non-enveloped viruses): REO-3: ≥6.4, HAV: ≥5.7, PPV: 4.1.

Conclusion: The Wilate® manufacturing process comprises two dedicated, efficient and robust virus inactivation steps, S/D and PermaHeat treatments. The total capacities [log10] for the individual viruses amount to ≥13.3 for HIV-1, ≥14.1 for SBV, ≥13.4 for PRV, ≥6.4 for REO-3, ≥5.7 for HAV, and 4.1 for PPV. Other production steps may contribute to virus reduction as well.

Topics:
detergents, factor viii, heat (physical force), human coagulation factor viii/von willebrand factor complex, solvents, viruses, von willebrand factor, hemophilia a, von willebrand disease, octoxynol

Author notes

Corresponding author

2005, The American Society of Hematology
2005
Sign in via your Institution